Overview

MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company’s first FDA approved product, in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. Our mission is to use our proprietary technologies and breakthrough discoveries to treat diseases and to create a better world.

Our values serve as the principle that guide all of our company’s actions; they serve as its cultural cornerstones.

Our employees are our number one asset, and we continue to be a tight-knit community where each of us has a critical role in our success, regardless of our physical location. Committed to diversity, at MannKind we depend on a rich blend of ideas, backgrounds, and working styles in our quest to change the world for the better.

WARNING:


If you are reporting an Adverse Event and/or device complaint, please contact MannKind Medical Information at 1-877-323-8505 or MannKind@druginfo.com. Do not use this form for adverse events and/or device complaints.

Close